39 reports of this reaction
2.3% of all NAFCILLIN SODIUM reports
#8 most reported adverse reaction
RENAL FAILURE is the #8 most commonly reported adverse reaction for NAFCILLIN SODIUM, manufactured by Athenex Pharmaceutical Division, LLC.. There are 39 FDA adverse event reports linking NAFCILLIN SODIUM to RENAL FAILURE. This represents approximately 2.3% of all 1,697 adverse event reports for this drug.
Patients taking NAFCILLIN SODIUM who experience renal failure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RENAL FAILURE is a less commonly reported adverse event for NAFCILLIN SODIUM, but still significant enough to appear in the safety profile.
In addition to renal failure, the following adverse reactions have been reported for NAFCILLIN SODIUM:
The following drugs have also been linked to renal failure in FDA adverse event reports:
RENAL FAILURE has been reported as an adverse event in 39 FDA reports for NAFCILLIN SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
RENAL FAILURE accounts for approximately 2.3% of all adverse event reports for NAFCILLIN SODIUM, making it a notable side effect.
If you experience renal failure while taking NAFCILLIN SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.